Mirtazapine for Sleep Disorders in Alzheimer's Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Brasilia University Hospital
Sponsor:
Information provided by (Responsible Party):
Einstein Francisco de Camargos, Brasilia University Hospital
ClinicalTrials.gov Identifier:
NCT01867775
First received: May 30, 2013
Last updated: June 3, 2013
Last verified: May 2013
  Purpose

The purpose of this study is to determine whether mirtazapine is effective in the treatment of sleep disorders in Alzheimers disease.


Condition Intervention Phase
Alzheimer's Disease
Sleep Disorders
Drug: Mirtazapine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Mirtazapine for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled Study

Resource links provided by NLM:


Further study details as provided by Brasilia University Hospital:

Primary Outcome Measures:
  • Change From Baseline in Nighttime Total Sleep Time [ Time Frame: Baseline, 14 days follow-up ] [ Designated as safety issue: No ]
    Mean of Nighttime Total Sleep Time (in minutes) during the 12-h nocturnal epoch 8:00 PM - 08:00 AM after 2 weeks under treatment


Secondary Outcome Measures:
  • Change From Baseline in Nighttime Number Of Awakenings [ Time Frame: Baseline, 14 days follow-up ] [ Designated as safety issue: No ]
    Change in scores from baseline to intervention week was analyzed using an analysis of covariance (ANCOVA) with the change score as the dependent variable and the treatment condition and baseline score as independent variables.

  • Change From Baseline in Nighttime Wake After Sleep Onset [ Time Frame: Baseline, 14 days follow-up ] [ Designated as safety issue: No ]
    Nighttime Wake After Sleep Onset (in minutes) after sleep onset until the final awakening during the 12-h nocturnal epoch 8:00 PM - 08:00 AM. After 2 weeks under treatment.

  • Change From Baseline in in Daytime Total Sleep Time [ Time Frame: Baseline, 14 days follow-up ] [ Designated as safety issue: No ]
  • Change From Baseline in Number of Daytime Naps [ Time Frame: Baseline, 14 days follow-up] ] [ Designated as safety issue: No ]
  • Change in Cognitive Function (as Measured by the Mini-Mental State Examination) [ Time Frame: Baseline, 14 days follow-up] ] [ Designated as safety issue: No ]
  • Change in Activities of Daily Living (The Index of ADL - Katz) [ Time Frame: Baseline, 14 days follow-up] ] [ Designated as safety issue: No ]
  • Change of Baseline in Behavioral Variables (BAHAVE-AD Scale) [ Time Frame: Baseline, 14 days follow-up] ] [ Designated as safety issue: No ]
  • Change From Baseline in Cognitive Function (Digit Symbol Substitution Test) [ Time Frame: Baseline, 14 days follow-up] ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: May 2012
Estimated Study Completion Date: May 2014
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Mirtazapine
Mirtazapine, 15 mg once a day, at night for 14 days
Drug: Mirtazapine
Mirtazapine 15 mg, at night, once a day for 14 days
Other Name: Remeron
Placebo Comparator: Placebo
Placebo 15 mg, once a day at night for 14 days

Detailed Description:

Mirtazapine has been used for depressed elderly with sleep disorders with good tolerability and efficacy. The study hypothesis is that mirtazapine could also be used in demented with sleep disorders.

Sleep disorders (SD) affects 35 to 50 percent of patients with Alzheimer Disease (AD). These disorders often make caring for patients at home very difficult and It's also associated with higher risk of institutionalization and increases health care costs. Treatment of SD in people with dementia may benefit both patients and their caregivers. However, little is known about the efficacy of pharmacological treatments for treating sleep disturbances in AD.

  Eligibility

Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Fifty-five years of age or older; Diagnosis of probable Alzheimer's disease by National Institute of Neurological and Communicative Disorders and Stroke/the Alzheimer's Disease and Related Disorders Association criteria; Hachinski Ischemia Scale score less than 5 Mini-Mental State Examination score of O to 26 Actigraph evidence of a mean time immobile of less than 7 hours per night based on at least 7 nights of complete actigraph data collected over a single week; For-week history of sleep disorder behaviors, occurring at least once weekly, as reported by the caregiver using the Neuropsychiatric Inventory (NPI) Nighttime Behavior scale; Sleep disturbance observed was not present before the diagnosis of AD; Other co-morbidities, especially delirium, depression, chronic pain and medication use may be present, but do not cooperate in the primary symptoms; Computed tomography or magnetic resonance imaging since the onset of memory problems showing no more than 1 lacunar infarct in a nonstrategic area and no clinical events suggestive of stroke or other intracranial disease or normal; Stable medications for 4 weeks prior to the screening visit; Having a mobile upper extremity to which to attach an actigraph; Residing with a responsible spouse, family member, or professional caregiver who is present during the night and would agree to assume the role of the principal caregiver for the 3-week protocol; Ability to ingest oral medication and participate in all scheduled evaluations

Exclusion Criteria:

Sleep disturbance associated with an acute illness, delirium or psychiatric disease; Clinically significant movement disorder, such as akinesia, that would affect actigraphic differentiation of sleep and wakefulness Severe agitation; Unstable medical condition; Discontinuation of psychotropic or sleep medications within 2 weeks of the screening visit; Patient unwilling to maintain caffeine abstinence after 2:00 PM for the duration of the protocol; Patient unwilling to comply with the maximum limit of 2 alcoholic drinks per day, and only 1 alcoholic drink after 6:00 PM for the duration of the protocol; Prior use of mirtazapine for the treatment of sleep disturbances; Caregiver deemed too unreliable to supervise the wearing of the actigraph, to administer trazodone the proper time, to maintain tbe sleep diary, or to bring the patient to the scheduled visits;

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01867775

Locations
Brazil
Brasilia University Recruiting
Brasilia, Distrito Federal, Brazil, 70840
Contact: Francisca M Scoralick       franciscascoralick@gmail.com   
Sub-Investigator: Francisca M Scoralick         
Sponsors and Collaborators
Brasilia University Hospital
Investigators
Principal Investigator: Francisca M Scoralick, MD University of Brasilia
  More Information

No publications provided

Responsible Party: Einstein Francisco de Camargos, Medical Doctor, Brasilia University Hospital
ClinicalTrials.gov Identifier: NCT01867775     History of Changes
Other Study ID Numbers: 052/2012
Study First Received: May 30, 2013
Last Updated: June 3, 2013
Health Authority: Brazil: Ethics Committee

Keywords provided by Brasilia University Hospital:
Alzheimer's disease
Sleep disorders
Mirtazapine
Treatment
Intervention
insomnia

Additional relevant MeSH terms:
Sleep Disorders
Parasomnias
Alzheimer Disease
Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Neurologic Manifestations
Signs and Symptoms
Pathologic Processes
Mirtazapine
Mianserin
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Histamine H1 Antagonists

ClinicalTrials.gov processed this record on September 22, 2014